A practical approach to the use of intravenous immunoglobulin in neurological disease

European Neurology

Volumn 39, Issue 1, 1998, Pages 3-8

  Wills, A J ^a   Unsworth, D J ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Guidelines; Intravenous immunoglobulin; Neurological indications

Indexed keywords

IMMUNOGLOBULIN;

HUMAN; IMMUNOTHERAPY; INTRAVENOUS DRUG ADMINISTRATION; NEUROLOGIC DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ADJUVANTS, IMMUNOLOGIC; AUTOIMMUNE DISEASES; DEMYELINATING DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; NERVOUS SYSTEM DISEASES; POLYRADICULONEUROPATHY; PRACTICE GUIDELINES; RISK FACTORS;

EID: 0031963277     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007891     Document Type: Review

References (56)

1. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T: Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-1611.
2. Duhem C, Dicato MA, Ries F: Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97(suppl 1):79-83.
3. Stiehm ER: Human gamma globulins as therapeutic agents. Adv Pediatr 1988;35:1-72.
4. Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 1986;314:560-564.
5. Hachimi Idrissi S, de Schepper J, de Waele M, Dab I, Otten J: Type III allergic reaction after infusion of immunoglobulins (letter). Lancet 1990;336:55.
6. Tan E, Hajinazarian M, Bay W, Neff J, Mendell JR: Acute renal failure resulting from intravenous immunoglobulin therapy. Arch Neurol 1993;50:137-139.
7. Sekul EA, Cupler EJ, Dalakas MC: Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: Frequency and risk factors. Ann Intern Med 1994;121:259-262.
8. Brox AG, Coumoyer D, Sternbach M, Spurll G: Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82:633-635.
9. Ayliffe W, Haeney M, Roberts SC, Lavin M: Uveitis after antineutrophil cytoplasmic antibody contamination of immunoglobulin replacement therapy (letter). Lancet 1992;339: 558-559.
10. Woodruff RK, Grigg AP, Firkin FC, Smith IL: Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients (letter). Lancet 1986;ii:217-218.
11. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996;47:674-677.
12. Ochs HD, Fischer SH, Virant FS, Lee ML, Kingdon HS, Wedgwood RJ: Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet 1986;ii:1062-1064.
13. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schoni M, Vest M, Wagner HP: High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;i:1228-1231.
14. Waldmann TA, Strober W: Metabolism of immunoglobulins. Prog Allergy 1969;13:1-110.
15. Blasczyk R, Westhoff U, Grosse Wilde H: Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-790.
16. Gajdos P: Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol 1994;97 (suppl 1):49-51.
17. Basta M, Fries LF, Frank MM: High doses of intravenous immunoglobulin do not affect the recognition phase of the classical complement pathway. Blood 1991;78:700-702.
18. Basta M, Dalakas MC: High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729-1735.
19. Andersson JP, Andersson UG: Human intravenous immunoglobulin modulates monokine production in vitro. Immunology 1990;71: 372-376.
20. Ruiz de Souza V, Carreno MP, Kaveri SV, Ledur A, Sadeghi H, Cavaillon JM, Kazatchkine MD, Haeffner Cavaillon N: Selective induction of interleukin-1 receptor antagonist and interleukin-8 in human monocytes by normal polyspecific IgG (intravenous immunoglobulin). Eur J Immunol 1995;25:1267-1273.
21. van der Meche FG, Schmitz PI: A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med 1992;326:1123-1129.
22. Bril V, Ilse WK, Pearce R, Dhanam A, Sutton D, Kong K: Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
23. Rees JH, Thompson RD, Hughes RAC: Does modern treatment improve the outcome of Guillain-Barré syndrome? (abstract). Ann Neurol 1996;40:508.
24. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ: Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
25. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C: Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986; 314:461-465.
26. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M: High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
27. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC: A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
28. Vermeulen M, van Doom PA, Brand A, Strengers PF, Jennekens FG, Busch HF: Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1993;56: 36-39.
29. Hahn AF, Bolton CF, Zochodne D, Feasby TE: Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: A double-blind, placebo-controlled, crossover study. Brain 1996;119:1067-1077.
30. van der Meche FG, Vermeulen M, Busch HF: Chronic inflammatory demyelinating polyneuropathy. Conduction failure before and during immunoglobulin or plasma therapy. Brain 1989;112:1563-1571.
31. Dalakas MC: Inflammatory and toxic myopathies. Curr Opin Neurol Neurosurg 1992;5: 645-654.
32. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, Dinsmore ST, McCrosky S: A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329: 1993-2000.
33. Bergamini L, Cocito D, Durelli L, Quattrocolo G: Opinions about plasma exchange and associated treatments in the therapy of myasthenia gravis (letter). Muscle Nerve 1983;6:457-458.
34. Gajdos P, Outin H, Elkharrat D, Brunel D, de Rohan Chabot P, Raphael JC, Goulon M, Goulon Goeau C, Morel E: High-dose intravenous gammaglobulin for myasthenia gravis (letter). Lancet 1984;i:406-407.
35. Cosi V, Citterio A, Lombardi M, Piccolo G, Romani A, Erbetta A: Effectiveness of steroid treatment in myasthenia gravis: A retrospective study. Acta Neurol Scand 1991;84:33-39.
36. Voltz R, Hohlfield R: The use of intravenous immunoglobulins in the treatment of neuromuscular disorders. Curr Opin Neurol Neurosurg 1996;9:360-366.
37. Edan G, Landgraf F: Experience with intravenous immunoglobulin in myasthenia gravis: A review. J Neurol Neurosurg Psychiatry 1994; 57:55-56.
38. Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN: A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
39. Azulay JP, Blin O, Pouget J, Boucraut J, Bille Turc F, Carles G, Serratrice G: Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 1994;44:429-432.
40. Bouche P, Moulonguet A, Younes Chennoufi AB, Adams D, Baumann N, Meininger V, Léger JM, Said G: Multifocal motor neuropathy with conduction block: A study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59:38-44.
41. Comi G, Amadio S, Galardi G, Fazio R, Nemni R: Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 1994:57(suppl): 35-37.
42. van den Berg LH, Franssen H, Wokke JHJ: Improvement of multifocal motor neuropathy during long-term weekly treatment with human immunoglobulin. Neurology 1995;45: 987-988.
43. Dyck PJ, Low PA, Windebank AJ, Jaradeh SS, Gosselin S, Bourque P, Smith BE, Kratz KM, Karnes JL, Evans BA et al: Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 1991;325:1482-1486.
44. Cook D, Dalakas M, Galdi A, Biondi D, Porter H: High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 1990;40:212-214.
45. Krendel DA, Costigan DA, Hopkins LC: Successful treatment of neuropathies in patients with diabetes mellitus. Arch Neurol 1995;52: 1053-1061.
46. Soueidan SA, Dalakas MC: Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43:876-879.
47. Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT: Inclusion body myositis: Treatment with intravenous immunoglobulin. Neurology 1994;44:1516-1518.
48. Amato AA, Cornman EW, Kissel JT: Treatment of stiff-man syndrome with intravenous immunoglobulin. Neurology 1994;44:1652-1654.
49. Vieregge P, Branczyk B, Barnett W, Stocker W, Soyka D, Kompf D: Stiff-man syndrome. Report of 4 cases. Nervenarzt 1994;65:712-717.
50. Achiron A, Cohen IR, Lider O, Melamed E: Intravenous immunoglobulin treatment in multiple sclerosis. Isr J Med Sci 1995;31:7-9.
51. Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S: High-dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry 1994;57 (suppl): 69-70.
52. Uchuya M, Graus F, Vega F, Rene R, Delattre J: Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry 1996;60:388-392.
53. Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S: Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: Correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994;17: 1073-1075.
54. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B: Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 1996;47:678-683.
55. van Rijckevorsel, Harmant K, Delire M, Schmitz Moorman W, Wieser HG:Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/ dose finding clinical study. Int J Clin Lab Res 1994;24:162-166.
56. Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G et al: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet 1995;345:365-369.